Priapism: a prolonged erection is an emergency

A painful erection that lasts more than 4 hours and has nothing to do with desire is not a sign of virility: it is a urological emergency. The longer you wait, the higher the risk of losing erections for good.

Illustration: Priapism

What are we talking about?

Priapism is an erection that lasts or persists with no connection to sexual stimulation and does not go away on its own (EAU, 2025). In practice, the 4-hour threshold is used: beyond it, the situation becomes urgent when the erection is painful. It is neither arousal nor a sign of “virility”: it is a blockage of blood circulation in the penis. Blood goes in, but it no longer comes out.

The condition is rare, but not exceptional: the European rare disease portal Orphanet classifies low-flow priapism (ORPHA:140949) with a prevalence of 1 to 9 per 100,000 people (Orphanet, 2026), the French Urology College guidelines give an incidence of 1.5 per 100,000 people (AFU, French Urology College guidelines), and a US study of emergency department visits (2006-2009) finds 5.34 cases per 100,000 men per year (Roghmann et al., 2013). The figures cannot be compared (different populations and methods), with two age peaks described between 7 and 10 years (sickle cell disease) and between 20 and 50 years (drug-related causes) (StatPearls, 2025); no national French measurement was found.

The three forms of priapism

Causes

Testosterone at a physiological dose does not cause priapism (EAU, 2025). In children, sickle cell disease is the main cause, far ahead of leukemia and injuries (EAU, 2025).

Time decides everything

Damage to the smooth muscle of the corpora cavernosa builds up with the duration of ischemia. The benchmarks from the guidelines:

Conversely, when the shunt is done within 24 hours, 78 to 100% of men regain spontaneous erections (EAU, 2025).

That window is not a guarantee. In a London series of 45 men who had a T-shunt with tunneling of the corpora cavernosa after first-line treatment failed, the priapism was relieved in every man whose episode had lasted less than 24 hours but in only 30% of those whose episode had lasted more than 48 hours; six months later the erectile function score (IIEF-5) had fallen on average from 24 to 7.7, erectile dysfunction was still present, according to the authors, in 50% of patients when the priapism had lasted less than 24 hours, and every man operated on after 48 hours had necrotic smooth muscle on biopsy and needed a penile prosthesis (Zacharakis et al., 2014). In an older Egyptian series, 15 of the 35 men reviewed on average 66 months after the episode (43%) had kept their erections; priapism lasting more than 48 hours and the lack of complete detumescence after treatment were the factors most closely linked to erectile dysfunction (El-Bahnasawy et al., 2002).

The 4 to 6 hour mark is a precaution rather than a threshold measured in men: a 2022 review notes that it rests on few animal studies and on a cavernous blood pH measured at an average of 6.9 after 4 to 6 hours, that in animals the smooth muscle still looks normal under the microscope after 6 to 8 hours of erection, and that several retrospective clinical series report preserved erections in many men whose priapism was relieved within 6 to 12 hours; data on erectile outcome are scarce for delays under 6 hours (Dekalo et al., 2022). This does not change what to do: seeking care from 4 hours on remains what the guidelines ask.

What to do right away

  1. Do not wait for it to pass. A painful erection that lasts does not reliably resolve on its own.
  2. Call emergency services (15 or 112 in France) or go to the emergency department if the erection goes beyond 4 hours (3 to 4 hours for the British health service), and from 1 hour in case of sickle cell disease (NHS, 2023). Do not drive yourself; get someone to go with you and bring your medicines (NHS, 2023).
  3. Say right at reception when it started, any sickle cell disease, any injection into the penis, your medicines (antipsychotics, antidepressants, anticoagulants) and any substances used: the care team uses this to choose the procedure (EAU, 2025).
  4. While waiting, the British health service suggests trying to urinate, taking a hot bath or shower, drinking plenty of water and walking, and advises against cold packs, sex, masturbation, alcohol and tobacco (NHS, 2023). Cold is cited among the “small measures” in the French guidelines (AFU, French Urology College guidelines), but the European and US guidelines consider these measures rarely effective (1 to 55% resolution in the European review, 75% failure of oral tablets) and note that cold can worsen a sickle cell crisis (EAU, 2025) (StatPearls, 2025) (Capogrosso et al., 2024): none of them should delay leaving for care.
  5. After an injection into the penis: do not inject again and do not take another erection medicine; the official leaflet advises against combinations (ANSM, 2014).

What happens in hospital

For ischemic priapism, treatment proceeds in stages (EAU, 2025):

For non-ischemic priapism, treatment starts with observation, perineal compression or ice, then embolization (closing the leaking artery, with 85.7 to 100% success and 75 to 100% preserved erectile function) is offered if the situation persists; surgery is the last resort (Carnicelli et Akakpo, 2018) (Milenkovic et al., 2024) (EAU, 2025). In a person with sickle cell disease, the urologist treats the erection without delaying the procedure, while the hematologist manages hydration, pain and oxygen (exchange transfusion is not the primary treatment for an acute episode) (AUA/SMSNA, 2022).

Preventing a recurrence

Afterwards: erection, sexuality and the couple

Prolonged low-flow priapism sometimes leaves erectile dysfunction and fibrosis of the corpora cavernosa (AFU, French Urology College guidelines). After a shunt, a follow-up visit takes place a few weeks later (AFU, 2012), and sex is not allowed for 4 to 6 weeks according to the sheet updated in 2025 (AFU, 2025). If the erection does not return, the prosthesis can restore a sex life with penetration (Sex Med Rev, 2024).

The impact is not only physical. In men with sickle cell disease, priapism is associated with shame and embarrassment, which delay speaking up and seeking care, and affects psychological, sexual and physical well-being (J Pediatr Hematol Oncol, 2022). In children, untreated ischemic priapism can leave erectile and psychosexual problems in adulthood (EAU, 2025). In the couple, fear of another episode at night, avoidance of intimacy or fear of impotence are things to talk about, with a doctor, a psychologist or a sex therapist. For ordinary erectile dysfunction and its treatments, see erectile dysfunction and erection medicines.

Common myths

When to seek care, and who to see

Any painful erection lasting more than 4 hours (1 hour in case of sickle cell disease) is an emergency: call emergency services (15 or 112 in France), or go to the nearest emergency department. For short episodes that keep coming back, or to talk about an erection that has become difficult after priapism, the family doctor, the urologist or the sex therapist are the right people: see Who to see, and when. This text is for information; it does not replace a doctor’s advice.

State of the research

The guidelines rely mainly on case series and observational studies: randomized trials are rare. For prevention in people with sickle cell disease, the 2020 Cochrane review finds only three small trials (stilbestrol, sildenafil, ephedrine or etilefrine) and concludes that evidence is lacking (Cochrane, 2020). Two phase 2 trials that were under way in 2022 have since reported results (Idris et al., 2022): in the randomized PIN trial (64 men with sickle cell disease followed for 10 months), moderate-dose hydroxyurea reduced monthly priapism frequency by 58.3% and hydroxyurea plus tadalafil by 66.3% compared with baseline, with no significant difference between the two arms and a decrease in sperm count and motility that reversed within 3 months of stopping; in the SPARTAN trial (36 patients), crizanlizumab reduced episodes by 46% at 26 weeks without reaching statistical significance (and its European marketing authorization was withdrawn in 2023) (Idris et al., 2025). The most recent international guidelines (2024, published in 2026) and European systematic reviews confirm the overall logic: assess urgently, treat ischemia quickly with aspiration and phenylephrine, abandon proximal shunts, do not rush a procedure for high-flow priapism, consider a prosthesis early after a failure (AUA/SMSNA, 2022) (Milenkovic et al., 2024) (ICSM, 2026). Research stopped on 18 November 2026.

The figures on duration and after-effects come mostly from single-centre case series (El-Bahnasawy et al., 2002) (Zacharakis et al., 2014) (Zacharakis et al., 2014), and the 4 to 6 hour mark rests on few animal studies (Dekalo et al., 2022): they give orders of magnitude, not exact thresholds.

Sources

  1. Notice de Caverject 20 µg/1 ml (alprostadil) — French medicines agency (ANSM), 2014 (in French): Official leaflet: seek emergency care if an erection lasts 4 hours or more.
  2. Incidence du priapisme aux urgences américaines — Journal of Urology, 2013: 5.34 emergency visits per 100,000 men per year (US, 2006-2009).
  3. Priapisme : diagnostic et prise en charge — Progrès en Urologie, 2018 (in French): French review: three types, medical then surgical treatment, embolisation.
  4. Traitements du priapisme chez les garçons et hommes drépanocytaires (revue Cochrane) — Cochrane, 2020: Systematic review: three trials, 102 participants, low to very low certainty.
  5. Surestime-t-on le risque de priapisme des IPDE5 ? — Journal of Sexual Medicine, 2020: Pharmacovigilance and published cases: PDE5 inhibitors account for 2.9% of drug-induced cases.
  6. Antipsychotiques et priapisme (revue) — Sexual Medicine Reviews, 2021: Review: about half of drug-induced priapism is attributed to antipsychotics.
  7. Impact du priapisme sur la vie des adolescents et adultes drépanocytaires — Journal of Pediatric Hematology/Oncology, 2022: Shame and embarrassment delay care; psychological, sexual and physical wellbeing affected.
  8. Diagnostic et prise en charge du priapisme récurrent, drépanocytaire et non ischémique (AUA/SMSNA) — American Urological Association, 2022: US guideline: emergency evaluation, recurrent, sickle cell and non-ischemic priapism.
  9. Épidémiologie et traitement du priapisme dans la drépanocytose — American Society of Hematology (ASH), 2022: Review: about a third of adult men with sickle cell disease affected, onset before puberty.
  10. Priapisme ischémique lié à la cocaïne : revue systématique et série — Actas Urológicas Españolas, 2024: Late presentation (over 40 hours on average) and poorer prognosis.
  11. Prothèse pénienne précoce ou différée dans le priapisme réfractaire (méta-analyse) — Sexual Medicine Reviews, 2024: Nine studies, 278 patients: early implantation reduces complications and fibrosis.
  12. Facteurs de risque et dysfonction érectile à long terme après priapisme (186 cas) — International Journal of Impotence Research, 2026: Risk of erectile dysfunction multiplied by 25 beyond 20 hours and by 61 beyond 36 hours.
  13. Priapisme : recommandations de la 5e consultation internationale de médecine sexuelle (ICSM 2024) — International Society for Sexual Medicine, 2026: 2024 international consensus published in 2026: diagnosis and treatment of priapism.
  14. Recommandations européennes de santé sexuelle et reproductive, chapitre Priapisme — European Association of Urology, 2025: Priapism chapter of the EAU guidelines: types, timing, blood gas, aspiration, phenylephrine, shunts, prosthesis, prevention.
  15. ALD n° 10 : syndromes drépanocytaires majeurs de l'adulte (PNDS) — French National Authority for Health, 2010 (in French): National care protocol for adult sickle cell disease, completed by the 2024 paediatric protocol.
  16. Priapism (painful erections) — NHS (United Kingdom), 2023: Public page: emergency after 3 to 4 hours, 1 hour with sickle cell disease.
  17. Fiche d'information patient : priapisme, shunt caverno-spongieux — French Association of Urology, 2012 (in French): Patient leaflet before a shunt: procedure, aftercare, risks.
  18. Référentiel du Collège d'urologie, chapitre Trouble de l'érection (priapisme) — French Association of Urology, 2024 (in French): French teaching reference: definition, low and high flow, stepwise treatment, shunt, embolisation.
  19. Fiche d'information patient : priapisme ischémique, shunt caverno-spongieux (mars 2025) — French Association of Urology, 2025 (in French): 2025 patient leaflet: no sexual intercourse for 4 to 6 weeks after surgery.
  20. Regimented Phosphodiesterase Type 5 Inhibitor Therapy Reduces Emergency Department Visits for Recurrent Ischemic Priapism — Journal of Sexual Medicine, 2021: Clinical cohort (24 evaluable patients on regimented daily PDE5 inhibitor): emergency visits reduced 4.4-fold and improvement in 92% of patients.
  21. Acute Ischemic Priapism: An AUA/SMSNA Guideline — Journal of Urology (AUA/SMSNA), 2021: US guideline: phenylephrine dilution (100 to 500 µg/ml), shunt rate reduced to 15-28% after aspiration-irrigation, abandonment of proximal shunts.
  22. Conservative and Medical Treatments of Non-Sickle Cell Disease-related Ischemic Priapism: EAU Systematic Review — International Journal of Impotence Research (EAU), 2024: EAU systematic review (59 studies): 70 to 100% detumescence with aspiration and sympathomimetics, 30 to 70% erectile dysfunction depending on duration.
  23. Surgical and Minimally Invasive Treatment of Ischemic and Non-ischemic Priapism: EAU Systematic Review — International Journal of Impotence Research (EAU), 2024: EAU systematic review (65 studies): abandonment of proximal shunts, high-flow embolisation (85.7 to 100% success, 75 to 100% preserved erection).
  24. Hydroxyurea With and Without Tadalafil for Prevention of Recurrent Priapism in Men With Sickle Cell Anemia (PIN Trial) — Blood (American Society of Hematology), 2025: Nigerian randomised trial (64 men with sickle cell anaemia): monthly episode reduction of 58.3% with hydroxyurea and 66.3% with hydroxyurea + tadalafil; summary of the SPARTAN trial.
  25. Priapism (StatPearls NBK459178) — StatPearls — NCBI Bookshelf, 2025: Clinical monograph (updated September 2025): microscopic timeline of ischaemia (6h to 72h), resolution rates with aspiration (33% to 66%) and phenylephrine (81 to 86%).
  26. Priapisme à flux réduit (ORPHA:140949) — Orphanet, 2026 (in French): European rare disease portal: prevalence of 1 to 9 per 100,000, ICD-10 N48.3 and ICD-11 GB06.1.
  27. Low-flow priapism: risk factors for erectile dysfunction — BJU International (El-Bahnasawy et al.), 2002: 35 men followed for a mean 66 months: 43% kept erections; priapism over 48 hours and lack of complete detumescence were the factors most linked to dysfunction.
  28. The efficacy of the T-shunt procedure and intracavernous tunneling (snake maneuver) for refractory ischemic priapism — Journal of Urology (Zacharakis et al.), 2014: 45 men treated with a T-shunt and tunneling: priapism relieved in all if under 24 hours, in 30% if over 48 hours; erectile score from 24 to 7.7 at 6 months.
  29. Penile prosthesis insertion in patients with refractory ischaemic priapism: early vs delayed implantation — BJU International (Zacharakis et al.), 2014: 95 men: prosthesis at a median of 7 days (96% satisfaction) or 5 months (60% satisfaction, second corporotomy in 80%).
  30. Priapism or prolonged erection: is 4-6 hours of cavernous ischemia the time point of irreversible tissue injury? — Sexual Medicine Reviews (Dekalo et al.), 2022: Review: the 4 to 6 hour mark rests on few animal studies; erections preserved in several series when priapism is relieved within 6 to 12 hours.

Official or institutional documents this page relies on, consulted on 18 November 2026. Links open in a new tab.

Content updated in .

Text written with the help of AI, under the editorial responsibility of CAPIT; human reviews are occasional (method and sources: About). This content does not replace medical or legal advice. Spotted an error? Write to us.

Locate this page in the site map